This prospectus contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical fact contained in this prospectus, including statements regarding our plans, objectives, goals, strategies, future events, future revenues or performance, financing needs, plans, or intentions relating to our product candidates and development programs and markets and business trends are forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections. In some cases, you can identify forward-looking statements because they contain words such as “aim,” “anticipate,” “assume,” “believe,” “can,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “positioned,” “potential,” “predict,” “project,” “seek,” “shall,” “should,” “target,” “will,” “would” or the negative of these words or other similar terms or expressions.
These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about:
| • | the timing of and costs involved in obtaining and maintaining regulatory approval of LTG-001, LTG-321, LTG-418 and any future product candidates that we may identify or develop; |
| • | the beneficial characteristics, including potential safety, efficacy and therapeutic effects of LTG-001, LTG-321 and LTG-418; |
| • | our ability to efficiently and cost-effectively conduct our current and future preclinical studies and clinical trials; |
| • | our ability to obtain funding for our operations necessary to complete further development and, if approved, commercialization of LTG-001, LTG-321 and LTG-418; |
| • | our ability to identify and develop LTG-001, LTG-321 and LTG-418 for treatment of additional indications; |
| • | the performance of our third-party service providers, including our suppliers and manufacturers; |
| • | the rate and degree of market acceptance and clinical utility for LTG-001, LTG-321, LTG-418 and any other product candidates we may develop; |
| • | the effects of competition with respect to LTG-001, LTG-321 and LTG-418 or any other product candidates we may develop, as well as innovations by competitors in our industry; |
| • | our estimates regarding the potential market opportunities and the number of patients for LTG-001, LTG-321, LTG-418 and any future product candidates, if approved for commercial use; |
| • | the implementation of our strategic plans for our business, LTG-001, LTG-321, LTG-418 and any future product candidates we may develop; |
| • | our intellectual property position, including the scope of protection we are able to establish, maintain, defend and enforce for intellectual property rights covering LTG-001, LTG-321, LTG-418 and any future product candidates we may develop; |
| • | regulatory and legal developments in the United States; |
| • | our ability to attract and retain employees and collaborators with development, regulatory and commercialization expertise; |
| • | the accuracy of our estimates regarding future expenses, future revenue, capital requirements and need for additional financing; |
| • | the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; |
| • | our expectations regarding the impact of global health pandemics, geopolitical conflicts and economic uncertainty, including interest rate changes and inflation on our business and operations, including clinical trials, collaborators, CROs and employees; |
| • | our anticipated use of the proceeds from this offering. |
These forward-looking statements reflect our management’s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this prospectus and are subject to risks and uncertainties. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. We discuss many of the risks associated with the forward-looking statements in this prospectus in greater detail in the section titled “Risk Factors.” Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements.
You should carefully read this prospectus and the documents that we have filed as exhibits to the registration statement, of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in this prospectus by these cautionary statements.
Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in any forward-looking statements, whether as a result of new information, future events, or otherwise.
